Prepregnancy GLP-1–Receptor Agonist Use and Pregnancy Outcomes

Given concerns about possible teratogenicity of glucagon-like peptide-1 (GLP-1)–receptor agonists, patients usually are advised to discontinue them at least 3 months before trying to conceive. Many patients regain weight when they stop taking GLP-1 agonists, and the potential effect of this weight gain on pregnancy is unknown.

Researchers examined medical records of ≈400 pregnancies with exposure to GLP-1 agonists and ≈1300 matched, unexposed pregnancies (mean body–mass index [BMI] immediately prior to pregnancy, 36 kg/m²; mean age, 34). The drug exposure period spanned 3 years preconception through 90 days postconception.